Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.
about
Modularity in protein complex and drug interactions reveals new polypharmacological propertiesSex and age differences in atrophic rates: an ADNI study with n=1368 MRI scansOptimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjectsBiomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsPerispinal etanercept: a new therapeutic paradigm in neurology.Vascular dementia
P2860
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@en
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@nl
type
label
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@en
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@nl
altLabel
Biomarkers for evaluation of c ...... mer’s and Parkinson’s diseases
@en
prefLabel
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@en
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@nl
P2093
P2860
P921
P1433
P1476
Biomarkers for evaluation of c ...... er's and Parkinson's diseases.
@en
P2093
Ilan Halperin
Moussa B H Youdim
Silvia A Mandel
P2860
P2888
P304
P356
10.1016/J.NURT.2008.10.033
P577
2009-01-01T00:00:00Z